

Seat No.: _____

Enrolment No. _____

GUJARAT TECHNOLOGICAL UNIVERSITY

M. Pharm. – SEMESTER – III • EXAMINATION – SUMMER • 2015

Subject Code: 930103

Date: 13-05-2015

Subject Name: Clinical Research and Pharmacy Practice

Time: 02:30 pm - 05:30 pm

Total Marks: 80

Instructions:

1. Attempt any five questions.
2. Make suitable assumptions wherever necessary.
3. Figures to the right indicate full marks.

- Q.1** (a) Explain drug discovery and development process. Discuss clinical phases of drug development. 06
- (b) Explain in brief about rationale for oral glucose tolerance test and glycated hemoglobin with clinical relevance. 05
- (c) Explain the concept of Essential drugs. Explain the properties and advantages of essential drugs. 05
- Q.2** (a) Write a note on biomarkers used in clinical biochemistry. Enlist various biomarkers and Write in brief about any one biomarker for hepatic and renal dysfunction with clinical interpretation. 06
- (b) Write in brief about review process of NDA. 05
- (c) Write a note on therapeutic Drug monitoring with suitable example. 05
- Q.3** (a) Describe the role of ICH in Pharmaceutical product quality. Mention the role and responsibilities of principal investigator and sponsor in the clinical studies. 06
- (b) Explain the role of cytochrome P450 superfamily enzymes in the biotransformation of various drugs. 05
- (c) Explain the effects of age on various pharmacokinetic parameters. 05
- Q.4** (a) Explain various factors responsible for altered drug disposition in pediatric population. 06
- (b) Write a note on investigator brochure for IND. 05
- (c) Write a note on critical care therapy with suitable example. Prepare list of drugs to be used in critical therapy. 05
- Q.5** (a) What is pharmacovigilance? How various phases of pharmacovigilance ensure safety throughout the lifecycle of a drug? 06
- (b) Write a note on periodic safety update reports (PSUR). 05
- (c) Describe the composition, role and responsibilities of IRB/IEC 05
- Q.6** (a) Write a note on pharmacokinetic drug-drug interaction. Evaluate following drug-drug interactions for its type, mechanism responsible, possible clinical outcomes and suggest corrective measure. 06
- i) Cholestyramine + Digoxin ii) Rifampin + Cyclosporine
- (b) Write a note on clinical manifestations of drug induced diseases. 05
- (c) Write a note on adverse drug reactions with special reference to its reporting. 05
- Q.7** (a) Explain briefly about treatment of acute drug poisoning. Write a note on acute barbiturate poisoning. 06
- (b) Define the term “Pharmacoeconomics”. Enlist different types and write a note on any one type of pharmacoeconomic evaluations. 05
- (c) Write a note on pharmacoepidemiology with its merits/demerits over randomized controlled trials 05